Summary：**Scientists Create Body‑Made Cancer Fighters, Offering Hope for Affordable Treatment** **Introduct

**Scientists Create Body‑Made Cancer Fighters, Offering Hope for Affordable Treatment**

**Introduction**
A breakthrough in immunotherapy has emerged from laboratories where researchers have engineered the body’s own cells to seek and destroy tumors. By reprogramming a patient’s immune cells to produce targeted anticancer agents directly inside the body, the new approach promises a potent yet potentially cheaper alternative to conventional cell‑based therapies. Early preclinical data show robust tumor shrinkage across several solid‑tumor models, sparking optimism that the strategy could broaden access to life‑saving treatment.

**Key Developments**
The team, led by scientists at a major U.S. research institute, harvested autologous T‑cells and equipped them with a synthetic gene circuit that triggers the secretion of a bispecific antibody when the cells encounter tumor antigens. This antibody simultaneously binds the cancer cell and a cytotoxic effector, recruiting the host’s immune system to eliminate the malignancy without the need for ex‑vivo manufacturing. In mouse models of melanoma and pancreatic cancer, a single infusion led to complete remission in over 60 % of subjects, with minimal signs of cytokine release syndrome—a common side effect of current CAR‑T therapies. Importantly, the engineered cells persisted for weeks, providing ongoing surveillance against relapse.

**Industry Analysis**
Current autologous CAR‑T products carry price tags exceeding $400,000 per patient, largely due to complex leukapheresis, genetic modification, and stringent quality‑control steps. The body‑made fighter platform sidesteps much of this infrastructure by performing the therapeutic conversion in vivo, which could cut production costs by an estimated 50‑70 %. Analysts note that if the technology scales successfully, it may disrupt the market dominance of centralized manufacturing facilities and encourage a shift toward point‑of‑care delivery. Regulatory pathways,